<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="765">
  <stage>Registered</stage>
  <submitdate>9/09/2005</submitdate>
  <approvaldate>9/09/2005</approvaldate>
  <nctid>NCT00168194</nctid>
  <trial_identification>
    <studytitle>Cellular Immune Responses to Hepatitis B Virus (HBV)- Longitudinal Follow up and Natural History</studytitle>
    <scientifictitle>Cellular Immune Responses to Hepatitis B Virus (HBV)- Longitudinal Follow up and Natural History</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>235/04</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Hepatitis B</healthcondition>
    <healthcondition>HIV Infections</healthcondition>
    <conditioncode>
      <conditioncode1>Infection</conditioncode1>
      <conditioncode2>Other infectious diseases</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Oral and Gastrointestinal</conditioncode1>
      <conditioncode2>Other diseases of the mouth, teeth, oesophagus, digestive system including liver and colon</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Infection</conditioncode1>
      <conditioncode2>Acquired immune deficiency syndrome (AIDS / HIV)</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions />
    <comparator />
    <control />
  </interventions>
  <outcomes />
  <eligibility>
    <inclusivecriteria>There are two groups of patients in this study. Group A mono-infected with Hepatitis B, and
        those with co-infection HBV/HIV.

        Group A inclusion criteria: (also split into 6 recruiting groups)

          -  Acute hepatitis B

          -  Chronic hepatitis B, HBV DNA+ve , normal ALT , HBeAg +ve

          -  Chronic hepatitis B, HBV DNA +ve , normal ALT, HBeAg -ve

          -  Chronic hepatitis , HBV DNA +ve, increased ALT, no HBV treatment B, HBeAg +ve

          -  Chronic hepatitis B, HBV DNA +ve , increased ALT, no HBV treatment B, HBeAg -ve

          -  Chronic hepatitis B, undergoing 'flare' of hepatitis

        Group B inclusion criteria:

          -  To be HIV/HBV co-infected

        All patients:

          -  To be over 18 years</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage />
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>-  Those who do not fit the inclusion criteria.</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Observational</studytype>
    <purpose />
    <allocation />
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment />
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing>Prospective</timing>
  </trial_design>
  <recruitment>
    <phase>Not Applicable</phase>
    <anticipatedstartdate />
    <actualstartdate>1/12/2004</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize />
    <actualsamplesize>104</actualsamplesize>
    <recruitmentstatus>Completed</recruitmentstatus>
    <anticipatedlastvisitdate />
    <actuallastvisitdate>1/12/2009</actuallastvisitdate>
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>VIC</recruitmentstate>
    <hospital>The Alfred Hospital, Commercial Road - Melbourne</hospital>
    <postcode>3004 - Melbourne</postcode>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Other</primarysponsortype>
    <primarysponsorname>The Alfred</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
    <othercollaborator>
      <othercollaboratortype>Government body</othercollaboratortype>
      <othercollaboratorname>National Institutes of Health (NIH)</othercollaboratorname>
      <othercollaboratoraddress />
      <othercollaboratorcountry />
    </othercollaborator>
  </sponsorship>
  <ethicsAndSummary>
    <summary>It remains unclear why some individuals are able to clear HBV from their bodies while in
      others HBV is a persistent infection. We plan to investigate this process by collecting blood
      and analysing how the patient's white blood cells respond to different pieces of the HBV
      virus. We will use new tools that can precisely tell us which component of the immune
      response may be different in individuals who are chronically infected with HBV and also in
      individuals who are also infected with HIV.

      The primary aims are therefore:

        1. To characterize HBV-specific T cell responses in HBV chronic carriers, and identify
           novel immunogenic regions in both HLA-A2+ and non-HLA-A2+ individuals.

        2. To determine the effect of HIV infection on HBV-specific T-cell responses</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT00168194</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Sharon Lewin, Professor</name>
      <address>Burnet Institute, Melbourne</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>